Browse POU4F1

Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF00046 Homeobox domain
PF00157 Pou domain - N-terminal to homeobox domain
Function

Multifunctional transcription factor with different regions mediating its different effects. Acts by binding (via its C-terminal domain) to sequences related to the consensus octamer motif 5'-ATGCAAAT-3' in the regulatory regions of its target genes. Regulates the expression of specific genes involved in differentiation and survival within a subset of neuronal lineages. It has been shown that activation of some of these genes requires its N-terminal domain, maybe through a neuronal-specific cofactor. Ativates BCL2 expression and protects neuronal cells from apoptosis (via the N-terminal domain). Induces neuronal process outgrowth and the coordinate expression of genes encoding synaptic proteins. Exerts its major developmental effects in somatosensory neurons and in brainstem nuclei involved in motor control. Stimulates the binding affinity of the nuclear estrogene receptor ESR1 to DNA estrogen response element (ERE), and hence modulates ESR1-induced transcriptional activity. May positively regulate POU4F2 and POU4F3. Regulates dorsal root ganglion sensory neuron specification and axonal projection into the spinal cord. Plays a role in TNFSF11-mediated terminal osteoclast differentiation. Negatively regulates its own expression interacting directly with a highly conserved autoregulatory domain surrounding the transcription initiation site. ; FUNCTION: Isoform 2: Able to act as transcription factor, cannot regulate the expression of the same subset of genes than isoform 1. Does not have antiapoptotic effect on neuronal cells.

> Gene Ontology
 
Biological Process GO:0001708 cell fate specification
GO:0001967 suckling behavior
GO:0003007 heart morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003223 ventricular compact myocardium morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0006354 DNA-templated transcription, elongation
GO:0006356 regulation of transcription from RNA polymerase I promoter
GO:0006360 transcription from RNA polymerase I promoter
GO:0006362 transcription elongation from RNA polymerase I promoter
GO:0007050 cell cycle arrest
GO:0007409 axonogenesis
GO:0007416 synapse assembly
GO:0007422 peripheral nervous system development
GO:0007498 mesoderm development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007631 feeding behavior
GO:0014706 striated muscle tissue development
GO:0016479 negative regulation of transcription from RNA polymerase I promoter
GO:0019230 proprioception
GO:0021535 cell migration in hindbrain
GO:0021536 diencephalon development
GO:0021538 epithalamus development
GO:0021545 cranial nerve development
GO:0021559 trigeminal nerve development
GO:0021675 nerve development
GO:0021953 central nervous system neuron differentiation
GO:0021986 habenula development
GO:0030900 forebrain development
GO:0030902 hindbrain development
GO:0032784 regulation of DNA-templated transcription, elongation
GO:0032785 negative regulation of DNA-templated transcription, elongation
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0045165 cell fate commitment
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0048644 muscle organ morphogenesis
GO:0048663 neuron fate commitment
GO:0048665 neuron fate specification
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048738 cardiac muscle tissue development
GO:0048880 sensory system development
GO:0048934 peripheral nervous system neuron differentiation
GO:0048935 peripheral nervous system neuron development
GO:0050808 synapse organization
GO:0050884 neuromuscular process controlling posture
GO:0050885 neuromuscular process controlling balance
GO:0050905 neuromuscular process
GO:0050957 equilibrioception
GO:0051355 proprioception involved in equilibrioception
GO:0051402 neuron apoptotic process
GO:0051705 multi-organism behavior
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055010 ventricular cardiac muscle tissue morphogenesis
GO:0060384 innervation
GO:0060415 muscle tissue morphogenesis
GO:0060537 muscle tissue development
GO:0061564 axon development
GO:0070997 neuron death
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0072331 signal transduction by p53 class mediator
GO:0090068 positive regulation of cell cycle process
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901796 regulation of signal transduction by p53 class mediator
GO:2001207 regulation of transcription elongation from RNA polymerase I promoter
GO:2001208 negative regulation of transcription elongation from RNA polymerase I promoter
Molecular Function GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001205 transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003697 single-stranded DNA binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0035326 enhancer binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804759: Regulation of TP53 Activity through Association with Co-factors
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between POU4F1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of POU4F1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of POU4F1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0920.772
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2070.69
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2970.502
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1290.884
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8750.493
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3930.334
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2380.79
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3030.8
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3740.797
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0270.947
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0270.964
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7010.0109
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of POU4F1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POU4F1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POU4F1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POU4F1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POU4F1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of POU4F1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between POU4F1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPOU4F1
NamePOU class 4 homeobox 1
Aliases BRN3A; POU domain class 4, transcription factor 1; Oct-T1; brn-3A; brain-3A; brain-specific homeobox/POU dom ......
Chromosomal Location13q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting POU4F1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.